NCT02372136

Brief Summary

In preterm infants fed human milk, milk needs to be fortified to meet nutrient recommendations. Fortification can be 1) standard, 2) individualized (adjusted based on daily human milk nutrient analysis and milk volume), or 3) optimized (adjusted based on growth rate and serum analyses). The first specific aim will determine whether individualized and optimized nutrition during hospitalization results in improved growth in the neonatal intensive care unit (NICU) in extremely low gestational age (GA) neonates (ELGANs, \<29 weeks) and in small for GA (SGA, birth weight \<10th percentile for GA) preterm infants compared with optimized nutrition. The second specific aim will determine whether individualized and optimized nutrition in the NICU improves neurodevelopmental outcomes (acquisition of development milestones) and reduces the risk of disproportionate growth (i.e., excess fat) in the NICU and findings suggestive of metabolic syndrome in the first 3 years of life.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 12, 2015

Completed
14 days until next milestone

First Posted

Study publicly available on registry

February 26, 2015

Completed
10 months until next milestone

Study Start

First participant enrolled

January 1, 2016

Completed
5.4 years until next milestone

Results Posted

Study results publicly available

May 20, 2021

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

July 3, 2024

Status Verified

June 1, 2024

Enrollment Period

8 years

First QC Date

February 12, 2015

Results QC Date

March 5, 2021

Last Update Submit

June 7, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Growth Velocity

    Rate of weight gain \[g x kg-1 x day-1\] and length velocity \[cm x week-1\]

    36 (range 35-37) weeks postmenstrual age or discharge (whichever comes first)

  • Linear Growth Velocity

    Increase in body length per week from birth to 36 weeks postmenstrual age or discharge

    36 (range 35-37) weeks postmenstrual age or discharge (whichever comes first)

Secondary Outcomes (14)

  • Disproportionate Growth (Increased Fat Mass): BMI >90th Centile

    36 (range 35-37) weeks postmenstrual age or discharge (whichever comes first)

  • Blood Pressure

    36 (range 35-37) weeks postmenstrual age or discharge (whichever comes first)

  • Hypertension or High Systolic Blood Pressure

    at 33-48 months adjusted age

  • Neurodevelopment

    18-41 months adjusted age (postnatal age corrected for prematurity)

  • Neurodevelopment

    18-41 months adjusted age (postnatal age corrected for prematurity) 18-41 months adjusted age (postnatal age corrected for prematurity) 18-41 months corrected age 18-41 months

  • +9 more secondary outcomes

Other Outcomes (2)

  • Mortality

    36 (range 35-37) weeks postmenstrual age or discharge (whichever comes first)

  • Necrotizing Enterocolitis

    36 (range 35-37) weeks postmenstrual age or discharge (whichever comes first)

Study Arms (2)

Individualized and Optimized Nutrition

EXPERIMENTAL

Individualized nutrition Optimized nutrition

Dietary Supplement: Individualized NutritionDietary Supplement: Optimized nutrition

Optimized Nutrition

OTHER

Optimized nutrition

Dietary Supplement: Optimized nutrition

Interventions

Individualized NutritionDIETARY_SUPPLEMENT

Intake of macronutrients (protein, fat, and carbohydrate) will be individualized every day by adding one or more macronutrients to human milk based on daily measurements using near-infrared analysis. In patients receiving less milk than 140 ml x kg-1 x day-1 fortification of human milk will be adjusted to reach at least the average concentrations of protein, fat, and carbohydrate in donor's milk (Wojcik. J Am Diet Assoc. 2009 Jan;109:137-40) and 20 cal/oz as provided by the Mother's Milk Bank of North Texas. In those receiving at least 140 ml x kg-1 x day-1 of milk at 24 cal/oz fortification will be adjusted to meet recent guidelines from the the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition (ESPGHAN) (Agostoni et al. J Pediatr Gastroenterol Nutr. 2010 Jan;50:85-91).

Also known as: Targeted, customized
Individualized and Optimized Nutrition
Optimized nutritionDIETARY_SUPPLEMENT

Milk fortification will be based on current recommendations and optimized by adjustment of nutrients once a week based on blood levels of urea nitrogen (corrected for serum creatinine level) and albumin and velocity of growth (weight and length).

Also known as: Adjustable
Individualized and Optimized NutritionOptimized Nutrition

Eligibility Criteria

AgeUp to 7 Days
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Preterm infants \<29 weeks GA and SGA infants \<35 weeks GA born at Parkland Health and Hospital System
  • Maternal plan to breastfeed or to use milk from the donor milk bank
  • From birth to 1 week of life

You may not qualify if:

  • Patients on comfort care only
  • Patients with major congenital abnormalities
  • Patients who are too unstable for the first 7 days to have an accurate length measurement

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UT Southwestern Medical Center

Dallas, Texas, 75390-9063, United States

Location

Related Publications (3)

  • Brion LP, Rosenfeld CR, Heyne R, Brown LS, Lair CS, Petrosyan E, Jacob T, Caraig M, Burchfield PJ. Optimizing individual nutrition in preterm very low birth weight infants: double-blinded randomized controlled trial. J Perinatol. 2020 Apr;40(4):655-665. doi: 10.1038/s41372-020-0609-1. Epub 2020 Feb 18.

    PMID: 32071367BACKGROUND
  • Reis JD, Heyne R, Rosenfeld CR, Caraig M, Brown LS, Burchfield PJ, Lair CS, Petrosyan E, Jabob T, Nelson DB, Brion LP. Follow-up of a randomized trial optimizing neonatal nutrition in preterm very low birthweight infants: growth, serum adipokines, renal function and blood pressure. J Perinatol. 2024 Jan;44(1):78-86. doi: 10.1038/s41372-023-01821-2. Epub 2023 Nov 14.

  • Reis JD, Tolentino-Plata K, Caraig M, Heyne R, Rosenfeld CR, Brown LS, Brion LP. Double-blinded randomized controlled trial of optimizing nutrition in preterm very low birth weight infants: Bayley scores at 18-38 months of age. J Perinatol. 2023 Jan;43(1):81-85. doi: 10.1038/s41372-022-01572-6. Epub 2022 Dec 6.

Related Links

MeSH Terms

Conditions

Infant, Premature, Diseases

Condition Hierarchy (Ancestors)

Infant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Results Point of Contact

Title
National Grant Gerber Foundation) (LPB); George L. MacGregor Professorship (CRR); National Children'
Organization
Gerber Foundation, UT Southwestern Med Ctr, Children's Medical Center

Study Officials

  • Luc P Brion, MD

    University of Texas Southwestern Medical Center

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Only the statistician and the formula technicians know the patients' allocation.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Pediatrics

Study Record Dates

First Submitted

February 12, 2015

First Posted

February 26, 2015

Study Start

January 1, 2016

Primary Completion

December 31, 2023

Study Completion

December 31, 2023

Last Updated

July 3, 2024

Results First Posted

May 20, 2021

Record last verified: 2024-06

Data Sharing

IPD Sharing
Will share

The datasets generated and/or analyzed during the current study will be available from the corresponding author on reasonable request after completion and publication of all follow-up data.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
after completion and publication of all follow-up data
Access Criteria
on reasonable request

Locations